These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37748492)

  • 1. Towards functional precision oncology with human organoids.
    Wang Z; Niu X; Cui C; Ouyang M; Li Q; Li Z; Liang L
    Lancet; 2023 Oct; 402(10412):1526-1527. PubMed ID: 37748492
    [No Abstract]   [Full Text] [Related]  

  • 2. Preclinical models for precision oncology.
    Ibarrola-Villava M; Cervantes A; Bardelli A
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):239-246. PubMed ID: 29959990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Patient-derived tumor organoids (or tumoroid) as valuable precision medicine tools].
    Perréard M; Florent R; Thorel L; Vincent A; Weiswald LB; Poulain L
    Med Sci (Paris); 2022 Nov; 38(11):888-895. PubMed ID: 36448894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of Genomic Profiling and Organoid Development in Precision Oncology.
    Yoon H; Lee S
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional precision oncology using patient-derived assays: bridging genotype and phenotype.
    van Renterghem AWJ; van de Haar J; Voest EE
    Nat Rev Clin Oncol; 2023 May; 20(5):305-317. PubMed ID: 36914745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An emerging role for cytopathology in precision oncology.
    Pauli C; Puca L; Mosquera JM; Robinson BD; Beltran H; Rubin MA; Rao RA
    Cancer Cytopathol; 2016 Mar; 124(3):167-73. PubMed ID: 26641771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Patient-derived tumor organoids (or tumoroid), a growing preclinical model for oncology].
    Thorel L; Florent R; Perréard M; Vincent A; Poulain L; Weiswald LB
    Med Sci (Paris); 2022 Nov; 38(11):880-887. PubMed ID: 36448893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards precision oncology in RET-aberrant cancers.
    Subbiah V; Roszik J
    Cell Cycle; 2017 May; 16(9):813-814. PubMed ID: 28318386
    [No Abstract]   [Full Text] [Related]  

  • 9. Organoids: An intermediate modeling platform in precision oncology.
    Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
    Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision medicine strategies in oncology: mixed approaches to matched therapies.
    Borcoman E; Le Tourneau C
    Future Oncol; 2018 Jan; 14(2):105-109. PubMed ID: 29224361
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient-derived induced pluripotent stem cells in cancer research and precision oncology.
    Papapetrou EP
    Nat Med; 2016 Dec; 22(12):1392-1401. PubMed ID: 27923030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
    Huntington SF; Davidoff AJ; Gross CP
    J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor organoids: Opportunities and challenges to guide precision medicine.
    Veninga V; Voest EE
    Cancer Cell; 2021 Sep; 39(9):1190-1201. PubMed ID: 34416168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rise of patient avatars in precision oncology.
    Ehlen L; Schmueck-Henneresse M
    Nat Biotechnol; 2024 Aug; 42(8):1173-1174. PubMed ID: 39060349
    [No Abstract]   [Full Text] [Related]  

  • 15. The Oncology Care Model at 5 Years-Value-Based Payment in the Precision Medicine Era.
    Mullangi S; Schleicher SM; Parikh RB
    JAMA Oncol; 2021 Sep; 7(9):1283-1284. PubMed ID: 34196666
    [No Abstract]   [Full Text] [Related]  

  • 16. Responsible use of organoids in precision medicine: the need for active participant involvement.
    Lensink MA; Jongsma KR; Boers SN; Noordhoek JJ; Beekman JM; Bredenoord AL
    Development; 2020 Apr; 147(7):. PubMed ID: 32253255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entering the era of precision medicine in pediatric oncology.
    Hadjadj D; Deshmukh S; Jabado N
    Nat Med; 2020 Nov; 26(11):1684-1685. PubMed ID: 33077957
    [No Abstract]   [Full Text] [Related]  

  • 18. [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].
    Pauli C; Moch H; Rubin MA
    Pathologe; 2017 Nov; 38(Suppl 2):160-168. PubMed ID: 28956107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global Precision Oncology: A Call to Action on Expanding Access to Targeted Cancer Therapies.
    Bharadwaj M; Vallurupalli M; Huang FW
    Oncologist; 2021 May; 26(5):353-355. PubMed ID: 33539588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug development in the era of precision medicine in oncology-Clues beyond randomization.
    du Rusquec P; Filleron T; Le Tourneau C
    Chin Clin Oncol; 2021 Jun; 10(3):23. PubMed ID: 33977726
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.